COCIR calls for costs consideration in planned EU medtech regulatory overhaul
This article was originally published in SRA
Executive Summary
Medtech companies operating in the EU are struggling enough in the current economic climate and any additional demands on them must be avoided, unless evidence proves new requirements are strictly necessary for safety1.